Candida central nervous system infection after neurosurgery: a single-institution case series and literature review
Hongwei Chen,Wenkai Cong,Dongcheng Xie,Shengjie Wang,Jianxing Niu,Guoqiang Chen,Xuanwei Dong,Qingming Zhou
DOI: https://doi.org/10.21037/apm-21-2577
Abstract:Background: Candida central nervous system (CNS) infection is a rare complication following neurosurgery. This disease often occurs during the treatment of bacterial CNS infection, and common bacterial culture results have a high false negative rate, which delays diagnosis and treatment, and seriously affect the prognosis of patients. The purpose of this study was to discuss the diagnosis, treatment process, and results of this disease through a small series of cases, so as to provide data support and a theoretical basis for the timely diagnosis and treatment of Candida CNS infection after neurosurgery. Methods: A retrospective analysis was conducted on eight patients with confirmed Candida CNS infection following neurosurgery in our department between June 2011 and June 2019. Their clinical symptoms, treatment schemes, outcomes, risk factors, and complications were analyzed. Results: Four patients received intravenous administration of fluconazole and were cured. Three patients received intravenous administration of amphotericin B. Two of them were cured, and the other died. One patient was cured after intravenous administration of voriconazole throughout the treatment. The overall cure rate was 87.5% (7/8), and the death rate was 12.5% (1/8). Among the three patients treated by amphotericin B, one patient suffered vomiting and renal function impairment. After drug discontinuation, this patient gradually improved. Another patient had acute renal failure, and the conditions were not improved after drug discontinuation. The remaining patient suffered from anemia and vomiting, which were relieved after drug discontinuation. One patient had hematuria during voriconazole treatment, and the symptoms were improved after the therapy was changed to fluconazole. Four patients treated with fluconazole did not have apparent adverse reactions. None of the cured patients relapsed during the 3-12 months follow-up after discharge. Conclusions: Candida CNS infection following neurosurgery is a rare condition; however, it may result in disastrous consequences. Early diagnosis and timely use of antifungal agents are considered the primary treatment principles. Blood culture of cerebrospinal fluid (CSF) is useful for early diagnosis. Fluconazole is the preferred choice for the clinical treatment of Candida CNS infection as it has both good efficacy and safety.